In Brief This Week: PerkinElmer; Becton Dickinson; Sigma-Aldrich; Cepheid; Pathway Genomics; Accelrys; Pressure Biosciences; Cellular Dynamics | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Mizuho Securities USA has upgraded its ratings on PerkinElmer and Becton Dickinson to Outperform from Neutral.

Analyst Peter Lawson raised PerkinElmer's rating and placed a $25 price target on its stock. He said the firm has less exposure to high-risk end markets, such as academic, pharma, and government, compared to its peers. He also said that business mix is more insulated from a cyclical downturn.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.